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Water and salt retention
Clinical trialsEndothelin receptor antagonists (ETRAs) are approved for the treatment of pulmonary hypertension and
scleroderma-related digital ulcers. The efforts to approve this class of drugs for renal indications, however, failed
so far. Preclinical studies were promising. Transgenic overexpression of ET-1 or ET-2 in rodents causes chronic
renal failure. Blocking the ET system was effective in the treatment of renal failure in rodent models. However,
various animal studies indicate that blocking the renal tubular ETAR and ETBR causes water and salt retention
partially mediated via the epithelial sodium transporter in tubular cells. ETRAs were successfully tested clinically
in renal indications in phase 2 trials for the treatment of diabetic nephropathy. They showed efﬁcacy in terms of
reducing albumin excretion on top of guideline based background therapy (RAS blockade). However, these
promising results could not be translated to successful phase III trials so far. The spectrum of serious adverse
eventswas similar to other phase III trials using ETRAs. Potential underlying reasons for these failures and options
to solve these issues are discussed. In addition preclinical and clinical studies suggest caution when addressing
renal patient populations such as patients with hepatorenal syndrome, patients with any type of cystic kidney
disease and patients at risk of contrast media induced nephropathy. The lessons learned in renal indications
are also important for other potential promising indications of ETRAs like cancer and heart failure.
© 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
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Shortly after the discovery of endothelin-1 (ET-1) in 1988, the entire
endothelin system was characterized (Barton and Yanagisawa, 2008).
The endothelin (ET) system consists of the three peptides, ET-1, ET-2
and ET-3, their G-protein-coupled receptors endothelin receptor A andthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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and ECE-2). The ETAR has a higher afﬁnity for ET-1 and ET-2 than for
ET-3, and the ETBR has an equal afﬁnity for all three endothelin
isopeptides (Masaki et al., 1994). The ET receptors belong to the family
of rhodopsin-like receptors with seven-transmembrane domains
coupled to different G proteins and are expressed on the cell surface.
However, also nuclear binding sites are described (Hocher et al.,
1992). The nonselective ETAR primarily mediates vasoconstriction and
thereby is involved in the pathogenesis of hypertension, endothelial
dysfunction, inﬂammation, and ﬁbrosis (Vignon-Zellweger et al.,
2012). The peptide-selective ETBR is mainly expressed in vascular
endothelial cells, mediates vasodilatation via a release of nitric oxide
and dilatory prostanoids and inhibits cell proliferation (Vignon-
Zellweger et al., 2012). However, ETAR and ETBR can have synergetic
or opposing effects depending on cell type, tissue type or physiological
situation (Vignon-Zellweger et al., 2012).
The very ﬁrst ETRAswere peptides and thusweremainly considered
research tools. Later Martine Clozel developed an orally available ETRA
later called bosentan (Clozel et al., 1994). Already shortly after the
discovery of ET-1, it became obvious that this new hormone plays a
key role in the pathogenesis of renal diseases. However, the efforts to
approve ETRAs for renal indications failed so far due to water and salt
retention. ETRAs are currently only approved for the treatment of
pulmonary hypertension and scleroderma-related digital ulcers
(Kohan et al., 2012).
Given the huge prevalence of water and salt retention as most
frequently seen side effects, an understanding of renal “ET pathophysi-
ology”with a special focus on safety is key for any clinical development
program. The review is thus focused on renal safety aspects of ETRAs. In
the ﬁrst part, however, we also brieﬂy describe experiments showing
that a primary – transgenic – activation of the ET system causes renal
damage on its own followed by a brief summary of preclinical and clin-
ical researchwith endothelin receptor blockers in diabetic nephropathy.
Lessons learned from rodent models overexpressing ET-1 or ET-2 in the
kidney
For the study of the endothelin system several transgenic animal
models have been created since its discovery in 1988. A murine animal
model transgenic for ET-1,with the transgene expressed predominantly
in brain, lung and kidney displayed a strong renal phenotype with the
development of renal cysts, interstitial ﬁbrosis of the kidneys, and
glomerulosclerosis leading to a progressive decrease in glomerular
ﬁltration rate. The observed pathologies are blood pressure indepen-
dent anddeveloped in spite of onlyminimally increased plasma concen-
trations of ET-1 (Hocher et al., 1997). This study further revealed that
ET-1 overexpressing mice show an induction of vascular inducible
NOS (iNOS) synthase expression in and around renal arteries, possibly
causing a local reset of the balance between vascular ET-1 and NO,
resulting in no alterations in blood pressure but chronic kidney inﬂam-
mation characterized by tissue inﬂammation (increased amount of
inﬁltrating macrophages and CD4+ lymphocytes). The molecular
mechanisms leading to this recruitment of immune cells, especially
around intrarenal arteries, in ET-1 transgenic mice remain unknown
so far (Hocher et al., 2004). The above described pathway is indepen-
dent of the classical ETB mediated NO release via ETB stimulation of
endothelial cells leading to an eNOS activation and subsequently to
NO formation (Barton and Yanagisawa, 2008; Masaki et al., 1994).
Very elegantwork in rodentmodelswith a vascular speciﬁc overexpres-
sion of ET-1 conﬁrmed the ﬁnding of ET-1 induced vascular inﬂamma-
tion. Moreover, using these models, it was shown that ET-1 plays a
role in the progression of atherosclerosis and abdominal aortic
aneurism formation by decreasing high-density lipoprotein and
increasing oxidative stress, inﬂammatory cell inﬁltration and matrix
metalloproteinase-2 in perivascular fat, vascularwall and atherosclerot-
ic lesions (Amiri et al., 2004; Li et al., 2013).It is important to realize that not only ET-1 modulates NO synthesis
either via the classical ET-1 - N ETB - N eNOS pathway or via ET-1
induced inﬂammation leading to an upregulation of iNOS (see above).
The opposite is also true: NO modulates the synthesis of ET-1. This
was demonstrated in elegant studies using either a pharmacological
approach to block NO synthesis with L-NAME or a genetic approach
(eNOS knockout mice) (Barton et al., 2000; Slowinski et al., 2007;
Tharaux et al., 1999). Thus, ET-1 and NO are part of a local paracrine
network controlling the synthesis of each other.
ET-2 transgenic rats are characterized by a glomerular expression of
ET-2, leading to signiﬁcantly increased ET-2 tissue concentrations
(Hocher et al., 1996a). These animals also developed glomerulosclerosis
with signiﬁcantly increased urinary protein excretion, but yet again the
observed pathologies were not caused by an increase in blood pressure.
These observations were in line with studies showing that an activated
renal paracrine endothelin system is involved in the pathogenesis of
glomerulosclerosis (Murer et al., 1994; Orisio et al., 1993; Roccatello
et al., 1994). The lack of hypertension in these models is most likely
due to the distinct expression pattern of the transgene and a counter-
regulation by other vasoactive systems, like the nitric oxide (NO) sys-
tem. Findings from studies investigating endothelin transgenic animals
suggest that there is a distinct renal effect of transgene overexpression
in the kidney. The changes observed are clearly independent of systemic
arterial blood pressure, while an isolated renal hypertension and/or
increased vascular resistance within the kidney might be present
(Liefeldt et al., 1999).
With the help of the ET-1 transgenic mouse model it was demon-
strated that overexpressing ET-1 also increases NO bioavailability
which counteracts the contractile potency of elevated ET-1 levels and
leads to an improvement of endothelium dependent relaxation. Thus,
in the presence of an activated ET system, up-regulation of NO produc-
tion is capable ofmaintaining vascular tone in a normal range and there-
fore can prevent the development of hypertension (Quaschning, 2003).
The hypothesis that ET transgenic animals do not develop hypertension
due to counterregulatory effects by the NO-system was further proven
correct by the generation of cross-bred animals of ET transgenic mice
and eNOS knockout mice. These animals displayed an even stronger
enhancement of blood pressure as compared to the already elevated
blood pressure in eNOS knockout mice (Quaschning et al., 2007).
To further elucidate the interaction between the ET and the NO
system (Quaschning et al., 2007) a transgenic mouse model carrying a
lacZ reporter gene construct under control of the human prepro-ET-1
gene promoter sequence was established. This revealed a close interac-
tion of the renal endothelin and nitric oxide system in a cell-type specif-
ic manner, whichwas especially displayed in renal tubular cells and to a
lesser extent in glomerular cells (Slowinski et al., 2007). This study
highlighted once more the strong interaction between the ET and the
NO system and a major role of ET in renal physiology during adulthood.
Data from transgenic animals show that in adult life the ET system is
most important in the renal and cardiovascular system as a chronically
activated ET system results in a blood pressure-independent ﬁbrosis of
different organs (Von Websky et al., 2009). Transgenic approaches
prove that a primary activation of the renal ET system causes kidney
damage on its own without other stimuli. The opposite is also true,
chronic kidney disease – classical studies were done in rats with 5/6
nephrectomy – activates the local renal ET system (Larivière et al.,
1997). The interaction of ET-1 and kidney disease thus represents a
vicious circle potentially potentiating each other. These observations
were a huge stimulus for research focused on developing drugs that
suppress the ET system in various ﬁbrotic diseases of the renal and
cardiovascular system.
Effects of ET receptor blockers in diabetic nephropathy
ET-1 involvement has been strongly implicated in the pathogenesis
and progression of several experimental models of chronic kidney
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pertensive nephrosclerosis, reduced renal mass and others (Benigni
et al., 1998, 2004; Dhaun et al., 2006; Kohan, 2010; Orisio et al., 1993).
More speciﬁcally, ET-1 contributes to proteinuria, kidney ﬁbrosis, and
renal inﬂammation in chronic kidney disease. A quite big amount of
data suggests that blocking ET receptors improves outcome in a subtype
of CKD, diabetic nephropathy. Already in 1998 it was demonstrated that
ETAR selective blockade reduced renal injury and improved function in
a rat model of diabetes. The observed effects of ETAR antagonism were
even stronger than what could be seen with ACE inhibition (Hocher
et al., 1998a). Soon after, Dhein et al. conducted a similar study, also
using a rat model of diabetes, investigating whether or not the long
term treatment with an ETAR antagonist improves outcome in compar-
ison to the established treatment with an angiotensin converting
enzyme (ACE) inhibitor. They showed that ETAR antagonism is effective
against the typical type I diabetic late complications and regarding renal
histological changes, ETAR antagonism is more effective than ACE
inhibition (Dhein et al., 2000). Until now, numerous other preclinical
studies have provided considerable proof of concept data regarding
the use of ETR antagonists for the treatment of diabetic nephropathy
(Gagliardini et al., 2009; Hocher et al., 2001; Sasser et al., 2007;
Watson et al., 2010; Zoja et al., 2011).
One question that prevailed for quite some time was whether
combined ETAR and ETBR antagonism as compared to a selective
ETAR antagonist would be preferable in treating diabetic nephropathy.
Saleh et al. showed that both selective blockade of ETAR and a combined
blockade of ETAR and ETBR reduced proteinuria and glomerular perme-
ability and restored glomerular ﬁltration barrier component integrity in
a ratmodel of diabetes. Yet only ETAR selective blockade elicitated anti-
inﬂammatory and antiﬁbrotic effects. The authors concluded that selec-
tive ETAR antagonists are more likely to be preferred for the treatment
of diabetic kidney disease (Saleh et al., 2011). This is in line with the
currently available evidence, also suggesting that an ETAR-selective
blockade is the more advantageous therapeutic approach (Kohan and
Pollock, 2013; Neuhofer and Pittrow, 2009). Interestingly, it was later
shown that concomitant ETBR antagonism could potentially even
complicate long-term treatment because of the importance of normal
ETBR function in avoiding ﬂuid retention (Kohan, 2009).
However, it is important to note that also combined ETA/ETB recep-
tor antagonists such as bosentan are beneﬁcial in experimental diabetic
nephropathy (Ding et al., 2003) and improve in patients with diabetes
endothelial function and microalbuminuria, key risk factors for disease
progression (Rafnsson et al., 2012).
Driven by the positive preclinical results, clinical trialswere initiated.
These trials reached phases II to III with various ETRAs (atrasentan,
avosentan, darusentan, and sitaxsentan) and as observed in preclinical
studies reduced proteinuria in patients with CKD (Dhaun et al., 2011;
Honing et al., 2000; Kohan et al., 2011; Mann et al., 2010; Wenzel
et al., 2009). Despite the success in preclinical studies, none of these
ETRAs has been approved by any regulatory agency for the treatment
of diabetic nephropathy. On the contrary, alarming observations of
long term adverse effects of ETAR antagonism were made in the
ASCEND study [A Randomised, Double Blind, Placebo Controlled,
Parallel Group Study to Assess the Effect of the Endothelin Receptor
Antagonist Avosentan on Time to Doubling of Serum Creatinine, End
Stage Renal Disease or Death in Patients With Type 2 Diabetes Mellitus
and Diabetic Nephropathy]. This study investigated the effects of
avosentan, a predominant ETAR antagonist, on progression of overt
diabetic nephropathy in a multicenter, multinational, double-blind,
placebo controlled trial. Also the ASCEND study was able to show that
avosentan signiﬁcantly reduces albuminuria when added to guideline-
based standard treatment in patients with type 2 diabetes and overt
nephropathy, as observed in previous smaller phase 2 clinical studies
of shorter duration (Wenzel et al., 2009). However, avosentan also
induced a signiﬁcant ﬂuid overload and congestive heart failure,
which leads to a premature termination of the ASCEND study due toan excess in cardiovascular events (Mann et al., 2010). This was a
huge drawback for the successful treatment of diabetic nephropathy
and CKD in general by ETRAs and led to a strong decline in further
studies. Currently, only atrasentan is still being actively studied for the
use in patients with CKD (Andress et al., 2012; Kohan et al., 2011). It is
currently the hope that the use of diuretics and a rather low dose of
atrasentan (minimizing side effect rates)may result in a positive beneﬁt
risk balance for the patients.
Based on the fact that blocking ET receptors causes ﬂuid retention,
maybe different approaches of modifying the ET system would have
avoided this severe adverse effect. Preclinical studies on diabetic rats
showed that treatment with a dual inhibitor of both neutral endopepti-
dase and endothelin-converting enzyme resulted in a decrease of renal
matrix protein content as well as protein and albumin excretion
independent of blood pressure. The effects were comparable to those
of angiotensin converting enzyme inhibition (Thöne-Reinke et al.,
2004). The beneﬁts of inhibiting both neutral endo-peptidase and
endothelin converting enzyme result from the different substrates
these enzymes process. Inhibiting endothelin converting enzymeblocks
the formation of ET-1, which results in positive effects on the progres-
sion of diabetic nephropathy. Additionally, by inhibiting the neutral
endopeptidase, the degradation of atrial natriuretic peptide (ANP) is
blocked. Increasing ANP plasma concentrations while concomitantly
inhibiting the ET system should be protective against salt and water
retention, as it is known that ANP provides a potent defensemechanism
against volume overload in mammals (Antunes-Rodrigues et al., 2004;
McGrath et al., 2005).
Safety issues with ET receptor antagonists (ETRAs)
Different ETRAs were tested in various clinical trials involving heart
failure, pulmonary arterial hypertension, resistant arterial hypertension,
stroke/subarachnoid hemorrhage and several forms of cancer. Results
from most of these trials were either negative or neutral, except for
pulmonary arterial hypertension and scleroderma-related digital ulcers.
Problems with study design, patient selection, drug toxicity, and drug
dosing were used to explain or excuse failures (Kohan et al., 2012).
Currently, a number of pharmaceutical companies who had developed
ETRAs as drug candidates have discontinued clinical trials or further
drug development, in some cases due to previously overseen serious
adverse effects (Mann et al., 2010).
It is interesting that ET antagonism induced testicular toxicity is
described in unpublished data of experimental animals and in drug
company product literature, but no peer reviewed study has yet
addressed this topic (Grass, 2001; Kohan et al., 2012; TRACLEER®).
Water and salt retention
ETRA-induced ﬂuid retention is a very stunning example of how an
adverse effect has affected the outcome of clinical trials and may the
future of thewhole class as a treatment option for CKD. It is noteworthy
that all ETRAs used in clinical trials, regardless of receptor isoform
speciﬁcity, cause ﬂuid retention, including bosentan, darusentan,
tezosentan, ambrisentan, sitaxsentan, avosentan, zibotentan and
atrasentan (Battistini et al., 2006). The degree of ﬂuid retention is
dose-dependent and is aggravated by diseases like congestive heart
failure and renal insufﬁciency. The impact of ﬂuid retention was best
illustrated by the failed ASCEND trial in patients with diabetic nephrop-
athy with glomerular ﬁltration rates between 15 and 60 ml/min (i.e.,
moderate to advanced CKD) (Mann et al., 2010). In retrospect, it turned
out that the doses employed in this trialwere too high. A previously per-
formed phase II study showed that avosentan displayed antiproteinuric
effects at substantially lower doses than those used in the ASCEND trial
and caused only modest ﬂuid retention (Wenzel et al., 2009).
The reasons why the higher doses of avosentan caused such signiﬁ-
cant ﬂuid retention are not completely understood. It is possible that in
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the ETBR. In vitro studies suggested that avosentan only has a relatively
modest selectively for the ETAR (50:1 ETAR:ETBR binding selectivity)
(Neuhofer and Pittrow, 2009), so, higher doses of avosentan may also
block the natriuretic and diuretic acting ETBR in the kidney. Another
possibility is that blockade of ETAR may also cause ﬂuid retention
which is dose dependent. Finally, the ASCEND trial involved patients
with more advanced kidney disease, who already are more prone to
developing ﬂuid retention (Rabelink and Kohan, 2011).
The renal collecting duct (CD) produces and binds more ET-1 than
any other region of the kidney and seems to be a key area for ET
mediated sodiumandwater handling. A large number of in vitro studies
demonstrated that ET-1 acts in an autocrine fashion to regulate CD
function (Kohan, 2011). The physiologic relevance of these ﬁndings
has been conﬁrmed in vivo by the generation of CD-speciﬁc ET-1 and
ETR knockouts (KOs) (Ahn et al., 2004; Ge et al., 2005a, 2005b, 2006,
2008). In CD-speciﬁc ET-1 KOs, plasma ET-1 levels are not affected,
but these animals show a reduced urinary excretion of ET-1. CD ET-1
KO mice are hypertensive but show no differences in body weight,
urine volume, creatinine clearance, sodium and potassium excretion,
urine and plasma osmolality, plasma aldosterone concentration
and renin activity. CD ET-1 KO mice are salt-sensitive and display a
reduced sodium excretion during the ﬁrst three days of a high salt
diet. Amiloride and furosemide are able to prevent sodium retention
and exacerbation of hypertension. However, they do not reduce blood
pressure in CD ET-1 KO mice on a normal sodium diet (Ahn et al.,
2004). Plasma vasopressin (AVP) concentrations are substantially
reduced in CD ET-1 KOmice, despite all other aspects of water metabo-
lism being similar. However, an increased renal sensitivity to the effects
of AVP can be observed, suggesting that ET-1 acts as a physiological
autocrine regulator of AVP action in the collecting duct (Ge et al.,
2005a). A CD-speciﬁc knockout of the ETAR has no effect on blood pres-
sure or urinary sodium excretion in mice, independently of salt intake
(Ge et al., 2005b). On the contrary, collecting duct ETBR knockout
mice have salt-sensitive hypertension (Ge et al., 2006). However,
collecting duct knockout of both ETAR and ETBR causes greater hyper-
tension and sodium retention than in mice with only ETBR disruption
(Ge et al., 2008), yet again underlining that both ET receptors are
involved in salt and water handling.
It is also known that the ET-1 gene is an early response gene of
aldosterone. Because aldosterone and ET-1 have opposing actions on
sodium reabsorption in the kidney, it was hypothesized that stimulation
of ET-1 by aldosterone acts as a negative feedbackmechanism localized
in the CD. Aldosterone-mediated sodium reabsorption is, at least in
part, caused by stimulating the epithelial Na channel (ENaC). In
contrast, ET-1 increases sodium andwater excretion through its binding
to receptors in the CD. Part of this effect may be due to decreased Na/
K-ATPase activity (Zeidel et al., 1989). However, current literature
suggests an inhibitory effect of ET-1 on the epithelial Na channel
(ENaC). Studies in cultured CD (Pavlov et al., 2010), distal nephron A6
cells (Gallego and Ling, 1996), and 3T3 cells stably expressing ENaC
(Gilmore et al., 2001) showed that ET-1 can reduce both channel open
probability and cell surface number of this sodium channel (Kohan,
2011). Experiments in isolated split open rat cortical CD showed that
ET-1 dynamically regulates ENaC open probability through a signaling
pathway including src kinases and MAPK1/2 (Bugaj et al., 2008). Other
signaling pathways have also been implicated in ET-1 dependent regula-
tion of distal nephron sodium transport likelymediated by ENaC. There is
strong experimental evidence that NO signaling plays a role in ET-1
regulation of distal nephron sodium handling (Schneider et al., 2008).
Similarly, modiﬁcation of medullary blood ﬂow and an increase in
production of locally derived signaling factors in response to ET-might
as well play a role in ET-1 mediated regulation of collecting duct sodium
transport (Brodsky et al., 2000; Escalante et al., 2002; Evans et al., 2001).
The relative physiological importance and the relationship between
these possible mechanisms of ET-1 control of ENaC remain unclear(Bugaj et al., 2008). In a very recent paper Lynch et al. further unraveled
how endothelin acts on ENaC. As seen previously, the presence of ET-1
signiﬁcantly inhibited ENaC mediated sodium reabsorption. Blockade of
either ETAR or ETBR restored this reabsorption to control rates. However,
only ETAR blockade restored a benzamil-sensitive component of sodium
reabsorption. By the addition of various speciﬁc channel blockers the
authors were able to demonstrate that ET-1 inhibits sodium reabsorption
in the cortical CD through both ETAR and ETBRmediated pathways. ETAR
blockade restored a benzamil-sensitive component of Na reabsorption,
which presumably was ENaC, whereas ETBR blockade restored a
benzamil-insensitiveNa reabsorptivemechanism. The authors concluded
that sodium reabsorption is mediated by ENaC in the cortical CD and
outer medullary CD and also by an ENaC independent mechanism in
the cortical CD Additionally, ET-1 inhibits sodium reabsorption through
both ETAR and ETBR mediated pathways (Jeanette Lynch et al., 2013).
Analyzing patients getting adverse events in the clinical trials using
endothelin receptor blockers, it became obvious that a main risk factor
for ﬂuid retention in humans seems to be the degree of kidney and
heart functions rather than selectivity of the ETR antagonist (Benigni
et al., 2004; Dhaun et al., 2006; Kohan, 2010; Kohan et al., 2012). In this
context, it is also puzzling that water and salt retention is not a major
issue in patients with pulmonary hypertension treated with endothelin
receptor antagonists. The underlyingmechanisms are poorly understood.
Acute renal failure
Until now, the pathogenesis of radiocontrast nephrotoxicity is not
completely understood, but it has been proposed that an imbalance
between vasodilation and vasoconstriction is causative for renal medul-
lary ischemia (Heyman et al., 1991). In animal models of radiocontrast
nephrotoxicity it was demonstrated that there is a signiﬁcant increase
in both plasma and urinary endothelin levels, during and after intrave-
nous radiocontrast infusion (Margulies et al., 1991). Furthermore, it
was shown that administration of ETRAs prevents renal vasoconstric-
tion in animal models of radiocontrast nephrotoxicity (Brooks and
DePalma, 1996; Cantley et al., 1993). However, these observations did
not translate into a treatment option for radiocontrast nephrotoxicity
in humans. In a multicenter, prospective, randomized study, investigat-
ing the use of a combined ETAR/ETBR antagonist in patients with CKD
undergoing radiocontrast assisted cardiac angiography, it was shown
that ER antagonismand intravenoushydration exacerbate radiocontrast
nephrotoxicity compared with hydration alone (Wang et al., 2000).
However, it is noteworthy that this phase 3 trial was not based on
phase 2 studies to establish the right dose. The authors and the respon-
sible company took a huge risk of failure by not having done a phase 2
program to deﬁne a potentially better dose for clinical use.
Polycystic kidney disease
Autosomal dominant polycystic kidney disease (ADPKD) is themost
common monogenic hereditary kidney disease in humans, which is
seen in about 1 in 1000 live births. This disease accounts for up to 10%
of all patients requiring renal replacement therapy (Hocher et al.,
1998b). An initial observation that ET-1 concentrations are markedly
elevated in Han:Sprague–Dawley rats, a model of human ADPKD as
well as in humans with ADPKD, gave rise to the hope of treating this
diseasewith the help of ETR antagonists (Hocher et al., 1998b). Contrary
to expectations, blocking ETAR or both ETAR and ETBR in Han:SPRD rats
was not associated with an amelioration of disease progression. ETAR
blockade even enhanced tubular cell proliferation, cyst number, and
size and reduced renal blood ﬂow. The additional blockade of the
ETBR attenuated these effects in Han:SPRD rats, whereas interstitial ﬁ-
brosis was enhanced by both compounds (Hocher et al., 2003). This
was a surprising observation, given that blocking the renal endothelin
system is usually a powerful antiﬁbrotic strategy in experimental
models of chronic progressive kidney ﬁbrosis (Braun et al., 1999;
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the negative results of ETRAs in ADPKD, other groups continued to
investigate ETAR or ETBR blockade in animal models of ADPKD,
reasoned by an availability of new, highly selective, orally active
nonpeptide ETRAs. Because ETBR had been shown to mediate tubular
cell proliferation in vitro, it was hypothesized that ETBR blockade
would decrease tubular cell proliferation (Chang et al., 2007). Unexpect-
edly, treatment with an ETBR antagonist leads to an exacerbation of the
renal cystic phenotype with a reduction in urine volume and sodium
excretion and increases in urine osmolarity and renal cAMP and ET-1
concentrations. Simultaneous ETAR blockade reversed the severe
changes that were seen after sole ETBR blockade. ETAR blockade alone
resulted in a signiﬁcant increase in tubular cell proliferation but did
not alter the cystic phenotype (Chang et al., 2007), which is consistent
with previous reports (Hocher et al., 2003).
Taken together, studies utilizing selective or non-selective ETAR and
ETBR antagonists to ameliorate cystic disease progression in rodent PKD
models have proven disappointing and do not support further exten-
sion into clinical trials. The results of these studies show that a critical
balance between ETAR and ETBR action in the cystic kidney appears to
be necessary to maintain kidney structure and function. Current
evidence suggests that ET-1 and its receptors act as major modifying
genes for renal disease progression in ADPKD but different approaches
are needed to translate these ﬁndings into clinical practice (Chang and
Ong, 2011).
Renovascular hypertension
In two kidney–one clip renovascular hypertension (2K1C), blood
ﬂow is reduced in the clipped kidney leading to ischemia, whereas in
the non-clipped kidney shear stress and blood pressure are increased.
Based on previous reports, which showed that parts of the paracrine
renal ET system (tissue ET-1 and ETAR density) are upregulated in the
clipped kidney in the late phase of renovascular hypertension in rats
with 2K1C renovascular hypertension (Diekmann et al., 2000), a study
was initiated investigating potential positive effects of endothelin
antagonism on reducing the progression of kidney ﬁbrosis. Long term
blockade of the activated endothelin system in the clipped kidney of
rats with renovascular hypertension using an ETAR antagonist did not
improve symptoms but lead to a ﬁbrotic atrophy of the clipped kidney.
The effects of ETAR antagonists on the non-clipped kidney were less
pronounced. Neither blood pressure nor plasma renin activity was sig-
niﬁcantly altered by ETAR blockade treatment. The authors suggested
that the ETAR blockade might reduce perfusion pressure in the clipped
kidney to a critical extent, thus causing ischemia induced ﬁbrotic atro-
phy, similar to what is observed when blocking the renin angiotensin
system with concomitant renal artery stenosis (Hocher et al., 2000).
Anemia
Anemia is a strong and independent risk factor for morbidity and
mortality in a number of chronic diseases (Akizawa et al., 2008;
Knight et al., 2004). One of the few authority approved applications of
ET antagonism is pulmonary hypertension (Dingemanse and van
Giersbergen, 2004). In a quite recent study it was shown that hemoglo-
bin levels closely parallel survival in patients with pulmonary hyperten-
sion. The authors point out that modiﬁcation of anemia in this disorder
could alter the clinical course and call for further research in this area
(Krasuski et al., 2011). However, in the abovementioned study no effect
of bosentan, a dual ETRA, on hemoglobin status could be seen. It is note-
worthy though that the total number of patients included in this study
was only 145 patients, of whom only 17% were treated with bosentan.
It is very likely that the number of patients receiving bosentan was too
low to observe any difference in occurrence of anemia. Actually, anemia
is a very common adverse effect of ETRAs, seen in various clinical trials
of several different compounds (Dingemanse and van Giersbergen,2004; Ma et al., 2012; Pulido et al., 2013; Vergouwen et al., 2012).
Current evidence suggests that the higher risk of anemia during treat-
mentwith an ET antagonistmight not just be an association but causally
linked to ET antagonism. In a study by Föller et al. it was shown in vitro
and in vivo that a stimulation of the ETBR inhibits suicidal erythrocyte
death, which is characterized by phosphatidylserine exposure at the
erythrocyte surface and triggered by increases in cytosolic calcium via
glucose withdrawal. ET1 and sarafotoxin 6c, an agonist of ETBR, did
not signiﬁcantlymodify cytosolic calciumactivity or phosphatidylserine
exposure in isotonic, glucose-containing, extracellular ﬂuid. Both ET1
and sarafotoxin 6c however, signiﬁcantly blunted the effect of glucose
withdrawal on phosphatidylserine exposure. The study also evaluated
the in vivo signiﬁcance of the ﬁndings. To this end rescued ETBR knock-
out and wild-type mice were used. The number of phosphatidylserine-
exposing erythrocytes, reticulocytes and spleen size was signiﬁcantly
larger in ETBR-KO mice than in wild-type mice. Spleens of ETBR-KO
mice also contained markedly more phosphatidylserine-exposing
erythrocytes than spleens from wild-type mice. The ETBR-KO erythro-
cytes were more susceptible to the eryptotic effect of oxidative stress
andmore rapidly cleared from circulating blood than ETBR-KO erythro-
cytes (Föller et al., 2010).
These results coming from animal studies could be of major clinical
signiﬁcance and should stimulate future clinical studies to assess
whether anemia during treatment with currently approved ET antago-
nists is due to suicidal erythrocyte death.
Pregnancy
Results from the different transgenic and knockout models show
that the ET system plays an important role in embryonic develop-
ment. Homozygous ET-1 KO mice display severe craniofacial abnor-
malities. These mice die soon after birth from asphyxia, because
they cannot breathe normally due to a missing jaw (Kurihara et al.,
1994). Furthermore they display malformations of the cardiovascular
system (Kurihara et al., 1995a), thymus and thyroid (Kurihara et al.,
1995b). No abnormalities in other organs such as the lung, kidney and
central nervous system can be observed. Similar craniofacial and cardio-
vascular malformations are seen in mice with disruption of the ETAR
gene (Clouthier et al., 1998). The important role of ET-1 in skeletal devel-
opment during intrauterine life was conﬁrmed by using prepro-ET-1-
lacZ-transgenic mice (Slowinski et al., 2007). The examination of expres-
sion patterns of ETARs and ET-1 suggests that ET-1/ETAR interaction is
essential in cranial bone and connective tissue formation as well as in
the development of the heart and its outﬂow tract (Clouthier et al.,
1998). In the case of ETBR knockouts, a developmental failure of epider-
mal melanocytes leads to a colorless spotted skin and an enteric neuron
defect that result in a megacolon, because the gastrointestinal tract
cannot undergo peristaltic movements anymore (Hosoda et al., 1994;
Shin et al., 1999).
Succeeding studies in which pharmacological blockade of the recep-
tor was tested at different timepoints throughout gestation identiﬁed
that blocking ETAR in early to mid-gestation resulted in phenotypical
birth defects similar to those seen in the knockout model (Taniguchi
and Muramatsu, 2003). All ETAR antagonists currently on the market
list pregnancy as a contraindication and the FDA recommends pregnan-
cy tests at frequent intervals while on treatment (Kingman et al., 2009).
It is known that endothelin plays an important role in one of the
most common pregnancy complications, preeclampsia (George et al.,
2012). Antagonism of the ETAR has been proven beneﬁcial in numerous
animal models of gestational hypertension, and it remains a putative
target for pharmacological intervention in this disease (George et al.,
2012). However, given the current state of knowledge, this seems
unlikely. The problem of teratogenicity might be manageable, as some
studies demonstrated that the administration of a selective ETAR antag-
onist only in late gestation has no teratogenic effect in either mice or
rats (Olgun et al., 2008; Thaete et al., 2001). But regarding the potential
146 C. Reichetzeder et al. / Life Sciences 118 (2014) 141–148of ET antagonism to cause salt and water retention, it appears not
beneﬁcial to use such a pharmacological approach as ﬂuid retention is
a pathognomonic feature of preeclampsia (Davison, 1997).
Hepatorenal syndrome
As a pathophysiological consequence, patients with impaired liver
function often develop renal failure. Depending on time course and
severity, we distinguish between type 1 and type 2 hepatorenal syn-
drome (HRS). Renal vasoconstriction is a key factor in the development
of HRS and may be secondary to increased activities of ET-1, a potent
renal vasoconstrictor. In rats, experimental liver cirrhosis by CCl4
(carbon tetrachloride) causes an up-regulation of the ETBR in the renal
medulla. Blocking this receptor with a non-selective ETAR/ETBR antago-
nist causes water and salt retention in these rats with CCl4-induced liver
cirrhosis (Hocher et al., 1996b). Despite these preclinical data, a clinical
study was initiated to test exactly the same hypothesis in humans. This
small, but well done study demonstrated, in line with the earlier preclin-
ical data, that endothelin receptor blockade potentially can cause a
deterioration in renal function in patients with liver cirrhosis and HRS
(Wong et al., 2008). Thus, caution should be taken in future studies
using endothelin receptor antagonists in patients with liver cirrhosis.
Conclusions
ETRAs are a very promising class of drugs for the treatment of
various cardiovascular and renal diseases. Preclinical work also suggests
the use of these drugs in various types of cancer such as prostate cancer.
However, the mode of action of ETRAs causes renal side effects in
general. All clinical development programs will face the fact that both
blocking the ETAR and also the ETBR causes water and salt retention.
Thus careful patient selection is essential — patients with a high
edema and/or water and salt retention risk should be excluded. In
addition, measures to monitor and treat these side effects are key
parts of any future clinical study. These class-related side effects are
manageable and should not block the clinical development of ETRAs
in the future. Besides these general points to consider, there are sub-
groups of patients with kidney diseases that should not receive ETRAs
based on our current knowledge. Data indicate that kidney function
may be worsened by blocking the ET system in:
• Chronic liver failure
• Any type of cystic kidney disease
• Patients at risk of AKI
• Patients with renovascular hypertension
In addition, recent experimental work showed that eNOS knockout
mice develop diastolic dysfunction, which could be rescued by ET-1
transgenic overexpression in the heart. This study furthermore
suggested that cardiac ET-1 overexpression in case of eNOS deﬁciency
interfered with the regulation of proteins playing a role in oxidative
stress, myocyte contractility, and energy metabolism (Vignon-Zellweger
et al., 2011). Thus, in conditions of diastolic heart failure with impaired
endothelial function it might not be a good idea to block the ET system
at all.
Moreover, there is a smart way to overcome the intrinsic side effect of
water and salt retention caused by pure endothelin receptor antagonists
that would merit more attention by clinical researchers in the future:
combined endothelin converting enzyme and neutral endopeptidase
inhibitors (Kalk et al., 2011; Sharkovska et al., 2011; Thöne-Reinke et al.,
2004; Wengenmayer et al., 2011). This new class of drugs may have all
the beneﬁcial effects of pure endothelin receptor blockade and may
solve the problem of water and salt retention at the same time by raising
plasma levels of naturetic peptides such as ANP (Kalk et al., 2011;
Sharkovska et al., 2011; Thöne-Reinke et al., 2004; Wengenmayer et al.,
2011).. However, clinical data with the new class of drugs are urgently
needed to allow ﬁrm statements. A head to head comparison of NEP/ECE inhibitors with ET receptor blocking agents in combination with
diuretics would generate important clinical information and guidance
for future clinical use.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.lfs.2014.02.025.Conﬂict of interest statement
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